Completed PHASE1 INTERVENTIONAL 1-arm NCT01743118

Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris

Phase Ib, Two-centre, Randomised, Observer-blind, Placebo- and Comparator Controlled Trial to Evaluate the Safety, Tolerability and Antipsoriatic Efficacy of Three Strengths of a Topical SPS4251 Formulation in a Psoriasis Plaque Test

Sponsor: Bioskin GmbH

Conditions Psoriasis Vulgaris

Interventions Daivonex® ointment Placebo SPS4251 Ointment

Updated 5 times since 2017 Last updated: Jul 16, 2013 Started: Mar 31, 2013 Primary completion: Jul 31, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Psoriasis Vulgaris, this trial is completed. The trial is conducted by Bioskin GmbH and has accumulated 5 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bioskin GmbH
Circassia Limited

Data source: Circassia Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany
• Hamburg, Germany